Keros Therapeutics (KROS) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free KROS Stock Alerts $55.19 -0.59 (-1.06%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKeros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Updateamericanbankingnews.com - April 16 at 1:26 AMKeros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Increase in Short Interestmarketbeat.com - April 15 at 2:25 PMAre Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?finance.yahoo.com - April 15 at 1:56 PMWCM Investment Management LLC Grows Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - April 14 at 10:45 AMVanguard Group Inc. Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - April 10 at 4:00 AMKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by SG Americas Securities LLCmarketbeat.com - April 6 at 4:15 AMBuy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012markets.businessinsider.com - March 29 at 11:22 AMQ1 2024 EPS Estimates for Keros Therapeutics, Inc. (NASDAQ:KROS) Lifted by William Blairmarketbeat.com - March 29 at 8:16 AMKeros Therapeutics (NASDAQ:KROS) Shares Gap Down to $66.11marketbeat.com - March 27 at 12:23 PMDyne Therapeutics appoints John Cox CEOmsn.com - March 25 at 9:08 AMKeros Therapeutics (NASDAQ:KROS) Trading Down 4.7%marketbeat.com - March 22 at 2:31 PMStrong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environmentmarkets.businessinsider.com - March 19 at 5:18 AMKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Buy" by Analystsmarketbeat.com - March 18 at 5:12 PMKROS Apr 2024 30.000 putfinance.yahoo.com - March 17 at 8:14 AMKROS Apr 2024 70.000 putfinance.yahoo.com - March 16 at 10:13 AMKROS Apr 2024 75.000 callfinance.yahoo.com - March 16 at 12:09 AMKROS Apr 2024 65.000 putfinance.yahoo.com - March 16 at 12:09 AMKeros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromesfinance.yahoo.com - March 14 at 8:30 AMKeros Therapeutics (NASDAQ:KROS) Shares Gap Down to $69.01marketbeat.com - March 5 at 1:23 PMKeros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conferencefinance.yahoo.com - March 5 at 10:12 AMCharles Schwab Investment Management Inc. Purchases 29,168 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - March 4 at 4:25 AMKeros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Estimates By $0.03 EPSmarketbeat.com - March 1 at 1:57 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)markets.businessinsider.com - March 1 at 1:13 PMBraidwell LP Purchases 213,444 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - March 1 at 10:18 AMKeros Therapeutics, Inc. (NASDAQ:KROS) Expected to Post FY2028 Earnings of $2.27 Per Sharemarketbeat.com - March 1 at 8:45 AMHC Wainwright Reiterates "Buy" Rating for Keros Therapeutics (NASDAQ:KROS)marketbeat.com - March 1 at 8:29 AMBuy Rating Affirmed for Keros Therapeutics Amid Positive Clinical Progress and Strategic Catalystsmarkets.businessinsider.com - March 1 at 8:12 AMKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 1 at 1:47 AMBuy Rating Justified by Keros Therapeutics’ Clinical Advancements and Strong Financial Positionmarkets.businessinsider.com - February 29 at 3:46 PMOptimistic Outlook for Keros Therapeutics’ Advancing Clinical Pipeline Justifies Buy Ratingmarkets.businessinsider.com - February 29 at 3:46 PMKeros Therapeutics (KROS) Set to Announce Earnings on Fridaymarketbeat.com - February 29 at 7:31 AMKeros Therapeutics Stock (NASDAQ:KROS), Earnings Estimates, EPS, and Revenuebenzinga.com - February 28 at 11:38 PMKeros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023finance.yahoo.com - February 28 at 6:37 PMKeros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 28 at 4:01 PMKeros Therapeutics (NASDAQ:KROS) Reaches New 52-Week High at $68.50marketbeat.com - February 27 at 10:44 AMFmr LLC Has $114.93 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - February 27 at 5:42 AMKROS Mar 2024 70.000 callfinance.yahoo.com - February 26 at 7:42 AMKeros Therapeutics (NASDAQ:KROS) Shares Up 4.8%marketbeat.com - February 23 at 1:59 PMKeros Therapeutics, Inc. (NASDAQ:KROS) Forecasted to Post FY2023 Earnings of ($5.28) Per Sharemarketbeat.com - February 23 at 6:34 AMRafferty Asset Management LLC Decreases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - February 23 at 5:47 AMCitigroup Inc. Has $3.13 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - February 22 at 5:24 AMKeros Therapeutics Stock (NASDAQ:KROS) Dividends: History, Yield and Datesbenzinga.com - February 21 at 11:03 PMDoes Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?finance.yahoo.com - February 21 at 12:58 PMKeros Therapeutics (NASDAQ:KROS) Reaches New 52-Week High at $62.29marketbeat.com - February 21 at 10:47 AMKeros Therapeutics (NASDAQ:KROS) Earns Outperform Rating from Analysts at William Blairmarketbeat.com - February 21 at 7:31 AMKROS Jun 2024 75.000 putca.finance.yahoo.com - February 20 at 12:00 AMKROS Sep 2024 30.000 putca.finance.yahoo.com - February 18 at 3:00 PMKROS Sep 2024 70.000 callfinance.yahoo.com - February 17 at 1:18 PMKROS Mar 2024 30.000 putfinance.yahoo.com - February 17 at 1:18 PMBarclays PLC Raises Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)marketbeat.com - February 17 at 5:27 AM Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto for 2024 (Ad)5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months. Get His #1 Coin For 2024 FREE By Clicking Here KROS Media Mentions By Week KROS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼0.980.45▲Average Medical News Sentiment KROS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼02▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Dyne Therapeutics News Maravai LifeSciences News TG Therapeutics News Rocket Pharmaceuticals News Amphastar Pharmaceuticals News Geron News Galapagos News PTC Therapeutics News Avidity Biosciences News Arvinas News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
